Nanjing Pharmaceutical Company Limited’s Net Profit Dropped 4.1% in First Three Quarters of 2023

Nanjing Pharmaceutical Company Limited (南京医药股份有限公司) (600713.SH) reported a net profit of 533 million yuan in the first three quarters of 2023, down 4.1% year-on-year.

Meanwhile, the company posted 40.5 billion yuan in revenue, up 8.3% year-on-year.

At the end of the reporting period, it had 33.2 billion yuan in total assets and 26.1 billion yuan in total liabilities, with a liability-to-asset ratio of 78.7%.